Qin, Shukui
Li, Jin
Bai, Yuxian
Shu, Yongqian
Li, Wei
Yin, Xianli
Cheng, Ying
Sun, Guoping
Deng, Yanhong
Zhong, Haijun
Li, Yunfeng
Qian, Xiaoping
Zhang, Liangming
Zhang, Jingdong
Chen, Kehe
Kang, Wenying
Bai, Yuxian
Shu, Yongqian
Li, Wei
Yin, Xianli
Cheng, Ying
Sun, Guoping
Deng, Yanhong
Zhong, Haijun
Li, Jin
Li, Yunfeng
Qian, Xiaoping
Qin, Shukui
Zhang, Liangming
Zhang, Jingdong
Chen, Kehe
Sun, Yuping
Lin, Yuan
Liu, Tianshu
Bai, Li
Cai, Shirong
Zong, Hong
Zhang, Helong
Wang, Wei
Sun, Sanyuan
Xiong, Jianping
Zhou, Jianfeng
Cao, Bangwei
Pan, Hongming
Luo, Suxia
Ba, Yi
Xu, Nong
Lu, Jianwei
Zhao, Jiemin
Zhang, Tao
Chen, Zhendong
Liang, Jun
Li, Qiu
Cao, Peiguo
Wang, Dong
Liao, Wangjun
Pan, Yueyin
Zhang, Longzhen
Tan, Yan
Liu, Yunpeng
Chen, Xi
Yang, Jianwei
Ma, Tao
Lin, Xiaoyan
Zeng, Shan
Zhang, Minghui
Wang, Xiuli
Li, Enxiao
Wan, Yiye
Yu, Guohua
Guo, Weijian
Yuan, Ying
Bai, Yuansong
An, Guangyu
Xu, Jianming
Yang, Lei
Liang, Houjie
Liu, Jiang
Wang, Wenling
,
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy, Safety, and Immunogenicity of HLX04
Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment
for Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase III
Study
https://doi.org/10.1007/s40259-021-00484-9
Funding for this research was provided by:
Shanghai Henlius Biotech, Inc.
Article History
Accepted: 20 April 2021
First Online: 20 May 2021
Declarations
:
: This study was sponsored by Shanghai Henlius Biotech, Inc.
: Wenying Kang is an employee of Shanghai Henlius Biotech, Inc. Shukui Qin, Jin Li, Yuxian Bai, Yongqian Shu, Wei Li, Xianli Yin, Ying Cheng, Guoping Sun, Yanhong Deng, Haijun Zhong, Yunfeng Li, Xiaoping Qian, Liangming Zhang, Jingdong Zhang, and Kehe Chen have no conflicts of interest that are directly relevant to the content of this article.
: Data are available from the corresponding author on reasonable request.
: The study was conducted in accordance with the International Council for Harmonisation guidelines on Good Clinical Practice and all applicable regulatory requirements, including the Declaration of Helsinki, and was approved by the ethics committees at each participating center.
: All participants provided written informed consent prior to study enrollment.
: Shukui Qin and Jin Li contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Yuxian Bai, Yongqian Shu, Wei Li, Xianli Yin, Ying Cheng, Guoping Sun, Yanhong Deng, Haijun Zhong, Yunfeng Li, Xiaoping Qian, Liangming Zhang, Jingdong Zhang, Kehe Chen and Wenying Kang. All authors reviewed and provided comments on the manuscript. All authors read and approved the final manuscript.